202 related articles for article (PubMed ID: 20065653)
21. Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.
Gustchina E; Bewley CA; Clore GM
J Virol; 2008 Oct; 82(20):10032-41. PubMed ID: 18667502
[TBL] [Abstract][Full Text] [Related]
22. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
[TBL] [Abstract][Full Text] [Related]
23. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis.
Tudor D; Derrien M; Diomede L; Drillet AS; Houimel M; Moog C; Reynes JM; Lopalco L; Bomsel M
Mucosal Immunol; 2009 Sep; 2(5):412-26. PubMed ID: 19587640
[TBL] [Abstract][Full Text] [Related]
24. Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region.
Nicely NI; Dennison SM; Spicer L; Scearce RM; Kelsoe G; Ueda Y; Chen H; Liao HX; Alam SM; Haynes BF
Nat Struct Mol Biol; 2010 Dec; 17(12):1492-4. PubMed ID: 21076400
[TBL] [Abstract][Full Text] [Related]
25. Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8.
Soto C; Ofek G; Joyce MG; Zhang B; McKee K; Longo NS; Yang Y; Huang J; Parks R; Eudailey J; Lloyd KE; Alam SM; Haynes BF; ; Mullikin JC; Connors M; Mascola JR; Shapiro L; Kwong PD
PLoS One; 2016; 11(6):e0157409. PubMed ID: 27299673
[TBL] [Abstract][Full Text] [Related]
26. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
[TBL] [Abstract][Full Text] [Related]
27. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.
Pancera M; McLellan JS; Wu X; Zhu J; Changela A; Schmidt SD; Yang Y; Zhou T; Phogat S; Mascola JR; Kwong PD
J Virol; 2010 Aug; 84(16):8098-110. PubMed ID: 20538861
[TBL] [Abstract][Full Text] [Related]
28. Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41.
Hrin R; Montgomery DL; Wang F; Condra JH; An Z; Strohl WR; Bianchi E; Pessi A; Joyce JG; Wang YJ
AIDS Res Hum Retroviruses; 2008 Dec; 24(12):1537-44. PubMed ID: 19102685
[TBL] [Abstract][Full Text] [Related]
29. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
Doria-Rose NA; Schramm CA; Gorman J; Moore PL; Bhiman JN; DeKosky BJ; Ernandes MJ; Georgiev IS; Kim HJ; Pancera M; Staupe RP; Altae-Tran HR; Bailer RT; Crooks ET; Cupo A; Druz A; Garrett NJ; Hoi KH; Kong R; Louder MK; Longo NS; McKee K; Nonyane M; O'Dell S; Roark RS; Rudicell RS; Schmidt SD; Sheward DJ; Soto C; Wibmer CK; Yang Y; Zhang Z; ; Mullikin JC; Binley JM; Sanders RW; Wilson IA; Moore JP; Ward AB; Georgiou G; Williamson C; Abdool Karim SS; Morris L; Kwong PD; Shapiro L; Mascola JR
Nature; 2014 May; 509(7498):55-62. PubMed ID: 24590074
[TBL] [Abstract][Full Text] [Related]
30. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody.
Kunert R; Wolbank S; Stiegler G; Weik R; Katinger H
AIDS Res Hum Retroviruses; 2004 Jul; 20(7):755-62. PubMed ID: 15307922
[TBL] [Abstract][Full Text] [Related]
31. A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition.
Lutje Hulsik D; Liu YY; Strokappe NM; Battella S; El Khattabi M; McCoy LE; Sabin C; Hinz A; Hock M; Macheboeuf P; Bonvin AM; Langedijk JP; Davis D; Forsman Quigley A; Aasa-Chapman MM; Seaman MS; Ramos A; Poignard P; Favier A; Simorre JP; Weiss RA; Verrips CT; Weissenhorn W; Rutten L
PLoS Pathog; 2013 Mar; 9(3):e1003202. PubMed ID: 23505368
[TBL] [Abstract][Full Text] [Related]
32. Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy.
Wang Q; Bi W; Zhu X; Li H; Qi Q; Yu F; Lu L; Jiang S
J Virol; 2015 Jul; 89(13):6960-4. PubMed ID: 25903343
[TBL] [Abstract][Full Text] [Related]
33. Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.
Zhou M; Meyer T; Koch S; Koch J; von Briesen H; Benito JM; Soriano V; Haberl A; Bickel M; Dübel S; Hust M; Dietrich U
Eur J Immunol; 2013 Feb; 43(2):499-509. PubMed ID: 23180650
[TBL] [Abstract][Full Text] [Related]
34. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
Julien JP; Huarte N; Maeso R; Taneva SG; Cunningham A; Nieva JL; Pai EF
J Virol; 2010 May; 84(9):4136-47. PubMed ID: 20147404
[TBL] [Abstract][Full Text] [Related]
35. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
[TBL] [Abstract][Full Text] [Related]
36. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation.
Alam SM; Liao HX; Dennison SM; Jaeger F; Parks R; Anasti K; Foulger A; Donathan M; Lucas J; Verkoczy L; Nicely N; Tomaras GD; Kelsoe G; Chen B; Kepler TB; Haynes BF
J Virol; 2011 Nov; 85(22):11725-31. PubMed ID: 21917975
[TBL] [Abstract][Full Text] [Related]
37. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.
van Dorsten RT; Lambson BE; Wibmer CK; Weinberg MS; Moore PL; Morris L
J Virol; 2020 Jan; 94(2):. PubMed ID: 31619559
[TBL] [Abstract][Full Text] [Related]
38. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.
Ofek G; Tang M; Sambor A; Katinger H; Mascola JR; Wyatt R; Kwong PD
J Virol; 2004 Oct; 78(19):10724-37. PubMed ID: 15367639
[TBL] [Abstract][Full Text] [Related]
39. F(ab')2 fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket.
Lu L; Wei M; Chen Y; Xiong W; Yu F; Qi Z; Jiang S; Pan C
Microbes Infect; 2013 Nov; 15(13):887-94. PubMed ID: 24141089
[TBL] [Abstract][Full Text] [Related]
40. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
